Category: Pharmaceutical Policy
Hatch-Waxman Act Explained: How the 1984 Law Balances Brand and Generic Drugs
By Joe Barnett On 24 Jun, 2026 Comments (0)
Explore how the Hatch-Waxman Act of 1984 revolutionized US drug policy by balancing patent protections for innovators with streamlined approvals for generics, lowering costs and increasing access.
View MorePost-market studies on generic drug safety: clinical follow-up
By Joe Barnett On 17 Jun, 2026 Comments (0)
Explore how post-market studies ensure generic drug safety through clinical follow-up, FDA surveillance, and adverse event reporting.
View MoreTendering Systems: Europe's Approach to Generic Purchasing Explained
By Joe Barnett On 10 Jun, 2026 Comments (10)
Explore how European tendering systems impact generic purchasing. Learn about open vs restricted procedures, the MEAT evaluation method, and strategies for winning public procurement contracts in the EU.
View MoreAuthorized Generics Explained: How They Differ from Brand and Traditional Generics
By Joe Barnett On 27 May, 2026 Comments (0)
Discover what authorized generics are and how they differ from brand-name and traditional generics. Learn about FDA regulations, pricing strategies, and how to identify them on your prescription.
View MoreHow Brand Manufacturers Produce Their Own Generic Versions
By Joe Barnett On 7 May, 2026 Comments (0)
Discover how brand manufacturers produce authorized generics to protect profits after patent expiration. Learn about the manufacturing process, pricing strategies, and consumer impact of this pharmaceutical tactic.
View MoreGlobal Biosimilar Markets: Europe vs United States Comparison
By Joe Barnett On 15 Apr, 2026 Comments (10)
A detailed comparison of biosimilar markets in Europe and the US, exploring regulatory shifts, patent cliffs, and the race for healthcare cost reduction.
View MoreGeneric Drug Shortages: The Paradox of Competition and Supply
By Joe Barnett On 14 Apr, 2026 Comments (0)
Explore the paradox of generic drug shortages: why more competition can actually lead to fewer manufacturers and unstable medical supplies.
View MoreRegulatory Exclusivity Explained: Non-Patent Market Protections in Pharma
By Joe Barnett On 26 Mar, 2026 Comments (8)
Regulatory exclusivity acts as a market protection tool separate from patents, blocking generic competition for specific periods. Learn how FDA rules shape drug pricing and availability.
View More
